Items where authors include "Drayson, M"
Article
Behrens, J, Gaskin, G, Iggo, N et al. (7 more authors) (2023) What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial. eJHaem, 4 (1). pp. 246-250. ISSN 2688-6146
Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055
Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055
Ramasamy, K, Sadler, R, Jeans, S et al. (17 more authors) (2022) Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. British Journal of Haematology, 197 (3). pp. 293-301. ISSN 0007-1048
Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (11 more authors) (2022) Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 107 (1). pp. 231-242. ISSN 0390-6078
Ramasamy, K, Sadler, R, Jeans, S et al. (15 more authors) (2022) COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 196 (1). pp. 95-98. ISSN 0007-1048
Bird, S, Cairns, D orcid.org/0000-0002-2338-0179, Menzies, T orcid.org/0000-0003-3896-7228 et al. (12 more authors) (2021) Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical Lymphoma Myeloma and Leukemia, 21 (10). pp. 667-675. ISSN 2152-2650
Bygrave, C, Pawlyn, C, Davies, F et al. (11 more authors) (2021) Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma. British Journal of Haematology, 193 (3). pp. 551-555. ISSN 0007-1048
Rana, R, Cockwell, P, Drayson, M et al. (8 more authors) (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Advances, 4 (22). pp. 5836-5845. ISSN 2473-9529
Pawlyn, C, Cairns, D orcid.org/0000-0002-2338-0179, Kaiser, M et al. (11 more authors) (2020) The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, 34 (2). pp. 604-612. ISSN 0887-6924
Johnson, DC, Lenive, O, Mitchell, J et al. (14 more authors) (2017) Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, 130 (14). pp. 1639-1643. ISSN 0006-4971